Negative regulation of the Wnt–β‐catenin pathway by the transcriptional repressor HBP1

In certain cancers, constitutive Wnt signaling results from mutation in one or more pathway components. The result is the accumulation and nuclear localization of β‐catenin, which interacts with the lymphoid enhancer factor‐1 (LEF)/T‐cell factor (TCF) family of HMG‐box transcription factors, which activate important growth regulatory genes, including cyclin D1 and c‐myc. As exemplified by APC and axin, the negative regulation of β‐catenin is important for tumor suppression. Another potential mode of negative regulation is transcriptional repression of cyclin D1 and other Wnt target genes. In mammals, the transcriptional repressors in the Wnt pathway are not well defined. We have previously identified HBP1 as an HMG‐box repressor and a cell cycle inhibitor. Here, we show that HBP1 is a repressor of the cyclin D1 gene and inhibits the Wnt signaling pathway. The inhibition of Wnt signaling and growth requires a common domain of HBP1. The apparent mechanism is an inhibition of TCF/LEF DNA binding through a physical interaction with HBP1. These data suggest that the suppression of Wnt signaling by HBP1 may be a mechanism to prevent inappropriate proliferation.

[1]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[2]  Karine Hovanes,et al.  β-catenin–sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer , 2001, Nature Genetics.

[3]  H. Varmus,et al.  Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer , 2000, Oncogene.

[4]  J. Zenklusen,et al.  Allelic loss at 7q31.1 in human primary ovarian carcinomas suggests the existence of a tumor suppressor gene. , 1995, Oncogene.

[5]  I. Bièche,et al.  Genetic alteration mapping on chromosome 7 in primary breast cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  H Clevers,et al.  Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium. , 1999, The American journal of pathology.

[7]  Chris Albanese,et al.  Inhibition of Cyclin D1 Kinase Activity Is Associated with E2F-Mediated Inhibition of Cyclin D1 Promoter Activity through E2F and Sp1 , 1998, Molecular and Cellular Biology.

[8]  M. Hung,et al.  b-Catenin , a novel prognostic marker for breast cancer : Its roles in cyclin D 1 expression and cancer progression , 2000 .

[9]  M. Bienz.  TCF: transcriptional activator or repressor? , 1998, Current opinion in cell biology.

[10]  Mariann Bienz,et al.  Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling , 1998, Nature.

[11]  H. Thirlwell,et al.  β-Catenin–Histone Deacetylase Interactions Regulate the Transition of LEF1 from a Transcriptional Repressor to an Activator , 2000, Molecular and Cellular Biology.

[12]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[13]  H. Shih,et al.  Regulation of Differentiation by HBP1, a Target of the Retinoblastoma Protein , 1998, Molecular and Cellular Biology.

[14]  C. Albanese,et al.  Transforming p21ras Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions (*) , 1995, The Journal of Biological Chemistry.

[15]  H. Clevers,et al.  Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. , 1999, Science.

[16]  Rudolf Grosschedl,et al.  Modulation of Transcriptional Regulation by LEF-1 in Response to Wnt-1 Signaling and Association with β-Catenin , 1998, Molecular and Cellular Biology.

[17]  P. Morin,et al.  β‐catenin signaling and cancer , 1999 .

[18]  I. Bièche,et al.  Location of several putative genes possibly involved in human breast cancer progression. , 1998, Cancer research.

[19]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[20]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[21]  Y. Hosokawa,et al.  Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele‐specific expression , 1998, Genes, chromosomes & cancer.

[22]  G. Austin,et al.  Cloning and expression of human HBP1, a high mobility group protein that enhances myeloperoxidase (MPO) promoter activity , 2001, Leukemia.

[23]  F. McCormick,et al.  Wnt Signaling to β-Catenin Involves Two Interactive Components , 2000, The Journal of Biological Chemistry.

[24]  Hui Zhang,et al.  Involvement of Retinoblastoma Protein and HBP1 in Histone H10 Gene Expression , 2000, Molecular and Cellular Biology.

[25]  Yusuke Nakamura,et al.  AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1 , 2000, Nature Genetics.

[26]  P. Polakis.  Wnt signaling and cancer. , 2000, Genes & development.

[27]  Hans Clevers,et al.  An HMG-box-containing T-cell factor required for thymocyte differentiation , 1995, Nature.

[28]  J. Zenklusen,et al.  Frequent loss of heterozygosity in human primary squamous cell and colon carcinomas at 7q31.1: evidence for a broad range tumor suppressor gene. , 1995, Cancer research.

[29]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[30]  David A. Case,et al.  Structural basis for DNA bending by the architectural transcription factor LEF-1 , 1995, Nature.

[31]  R. Grosschedl,et al.  Regulation of LEF-1/TCF transcription factors by Wnt and other signals. , 1999, Current opinion in cell biology.

[32]  H. Clevers,et al.  Linking Colorectal Cancer to Wnt Signaling , 2000, Cell.

[33]  Hans Clevers,et al.  Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4 , 1998, Nature Genetics.

[34]  Aaron M. Zorn,et al.  Regulation of Wnt Signaling by Sox Proteins: XSox17α/β and XSox3 Physically Interact with β-catenin , 1999 .

[35]  Tony Kouzarides,et al.  The HMG-box transcription factor HBP1 is targeted by the pocket proteins and E1A , 1997, Oncogene.

[36]  H. Clevers,et al.  The Yin-Yang of TCF/beta-catenin signaling. , 2000, Advances in cancer research.

[37]  Hans Clevers,et al.  The TAK1–NLK–MAPK-related pathway antagonizes signalling between β-catenin and transcription factor TCF , 1999, Nature.

[38]  S. Smerdon,et al.  Human HMG box transcription factor HBP1: a role in hCD2 LCR function , 1999, The EMBO journal.

[39]  I. Bièche,et al.  (C-A)n microsatellite repeat D7S522 is the most commonly deleted region in human primary breast cancer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  A. Leiter,et al.  HMG Box Transcriptional Repressor HBP1 Maintains a Proliferation Barrier in Differentiated Liver Tissue , 2001, Molecular and Cellular Biology.

[41]  Christopher J. Thorpe,et al.  MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans , 1999, Nature.

[42]  H. Shih,et al.  HBP1: a HMG box transcriptional repressor that is targeted by the retinoblastoma family. , 1997, Genes & development.

[43]  R. Nusse,et al.  WNT targets. Repression and activation. , 1999, Trends in genetics : TIG.

[44]  P. Nowell,et al.  Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Merino,et al.  Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.

[46]  M. Hung,et al.  β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression , 2000 .

[47]  Elaine Fuchs,et al.  A common human skin tumour is caused by activating mutations in β-catenin , 1999, Nature Genetics.

[48]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  H. Koeffler,et al.  Allelotyping of acute myelogenous leukemia: loss of heterozygosity at 7q31.1 (D7S486) and q33-34 (D7S498, D7S505). , 1999, Leukemia research.